Clinical trial
Study on Predicting Response of Recurrent Glioblastoma to Apatinib
NCT04814329 is registered in ClinicalTrials.gov with Beijing Sanbo Brain Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study on Predicting Response of Recurrent Glioblastoma to Apatinib
- Lead sponsor
- Beijing Sanbo Brain Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 22, 2021
- Completion date
- June 30, 2023
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.